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Abstract
Cell  therapy  is  presently  a  treatment  of  choice  for  many  types  of  haematological  and
metabolic diseases and is likely to become a therapeutic option for other severe human
diseases and conditions in the near future. The success of cell transplantation depends on
a  variety  of  factors,  including  the  degree  of  HLA  match  between  the  donor  and  the
recipient, the infectious burden of the graft, cell dosage, age, general state of the recipient
and other incompletely characterised features of the donor and the recipient. It is likely that
the individual capacity for identiﬁcation and repair of DNA damage and maintenance of
genomic integrity may account,  at  least  in part,  for  these elusive factors that  modulate
transplantation  outcome in  terms  of  success  rate  and  both  long  and  short  term post-
transplantation complications. This paper outlines the role of individual repair capacity of
the donor and recipient in cell transplantations, summarising the little knowledge already
accumulated in the ﬁeld whilst analysing the known major issues of the use of diﬀerent
types of stem cells. Attention will be given to their capacity to maintain the integrity of their
genome, the ability to renew their own population, diﬀerentiate into various cell types and in
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some cases, succumb to carcinogenic transformation. Analysis of the individual capacity
may become a useful tool in the assessment of the suitability of a set of freshly collected
stem cells or an in vitro propagated cell line for potential clinical applications.
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1. Transplantation of Cells and Tissues – from desperate
measures to (almost) complete cures for severe terminal
disease
The idea of treating physical disease or reconstructing injured tissue by transplantation of
healthy tissues and organs has fascinated clinicians throughout human history. There is
suﬃcient evidence that the surgical techniques needed for harvesting and transplantation
of skin were already developed in the past (Kiel 1978). Very early on however, it was noted
that cross-transplantation between diﬀerent individuals were unsuccessful;  therefore the
attempts to cure by transplantation were, up to the beginning of the 20  century, limited to
auto-transplantation of tissues (mostly skin, but occasionally bone in rare circumstances).
The  advent  of  allogenic  tissue  transplantations  began  in  1905  with  the  successful
transplantation of the cornea, performed by Eduard Zirm. Zirm used an enucleated eye
from  an  unrelated  donor,  to  a  recipient  with  bilateral  chemical  burns  of  the  cornea
(Armitage 2006). The surgery could be described as 50% successful as the transplant in
one eye was rejected, but a success in the other, resulting in signiﬁcant improvement of
visual  activity  of  the  recipient.  The decades following this  ground-breaking intervention
however  were disastrous,  with  many attempts  at  transplantation of  organs and tissues
between unrelated donors and recipients almost invariably ending in disaster. Henceforth,
transplants were generally limited to procedures performed between genetically identical
individuals (monozygotic twins), however there are some ‘last resort’ attempts to save the
life of the terminally ill with transplantations from living or cadaveric donors, with the latter
being generally unsuccessful. The ﬁrst successful transplantation of haematopoietic stem
cells (HSCs) from bone marrow were conducted in 1956 by a team under Edward Donnell
Thomas in New York, USA. The donor and recipient in this case were identical twins.
There have been several documented attempts to alleviate aplastic anaemia resulting from
acute  irradiation  incidents  by  infusion of  bone  marrow  suspensions  from  related  or
unrelated donors, however each instance has been, on the whole, unsuccessful and the
reasons  for  this  are  unclear  (Cosset  2002).  Once  the  material  carriers  of  biochemical
individuality  were  discovered,  thanks  to  the  works  of  Jean  Dausset  and  Rose  Payne
(DAUSSET and BRECY 1957, Payne and Hackel 1961, it became clear that the ﬁrst and
foremost  determinant  of  the  success  of  any  type  of  allogenic  transplantation  was  the
degree of tissue compatibility between the donor and the recipient. It was from this point on
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that  reliable  identiﬁcation of  compatible  donor-recipient  pairs  became one of  the major
tasks  of  clinical  and  transplantation  science.  This  allowed,  on  one  hand,  for  the
assessment of potential success of the transplantation before intervention whilst on the
other hand, allowing for the development of approaches to induce the recipients’ tolerance
of allogenic transplants. This methodology for HLA typing has been developing steadily in
the second half of the 20  century, allowing resolution up to allele level. As a result, the
number of transplantations of cells, tissues and organs (on occasion, more than one organ
in a single transplantation) has been increasing since the 1970’s.
The type of  cells  most  commonly used for  transplantations (historically  and today)  are
haematopoietic stem cells obtained from the bone marrow or peripheral blood from adult
donors, or cord blood collected at birth.  Over the last few decades, transplantations of
haematopoietic stem cells have become have become an option of choice in the treatment
of  haematological  malignancies,  aplastic  anaemia,  myelodysplastic  syndrome,  severe
immune deﬁciencies and some types of  metabolic  disorders,  provided that  a  matching
transplant is readily available or likely to be shortly. The average waiting time for ﬁnding a
potential match in the donor databases has decreased in the last decades (usually from
weeks to months in some cases, however this may be longer in ethnic groups) and has
been greatly facilitated by the improved communication between diﬀerent centres, allowing
identiﬁcation of a suitable donor with a single search in multiple databases. For 2014, over
40,000 transplantations of HSCs performed in 47 countries were reported (Passweg et al.
2016). Nevertheless, HLA haplotype diversity of stored HSCs is still an issue, especially for
minority ethnic groups and individuals of mixed ancestry. Within the last 15 years, much
research has been conducted into the potential  clinical use of mesenchymal stem cells
(MSCs), embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) as they
provide opportunities for a source of more than one type of diﬀerentiated cells (in the case
of  ESCs,  virtually  all  types  of  diﬀerentiated  cells  of  the  human  body).  Indeed,  HSC
transplantations are saving lives today, whereas the transplantations of MSCs are still at a
clinical trial level, with ESCs still very much so a far cry from clinical use. At present, it is
believed that it is only a matter of time and eﬀort before cell therapy becomes a principal
treatment for many more severe and previously incurable conditions.
There have always been signiﬁcant concerns about the safety of cell therapies. Originally,
these were mainly concerns about  transmission of  blood-borne infections.  The case of
David Vetter in 1983 however resulted in an increase of these safety concerns. As it had
turned out, it was not only known pathogens (such as hepatitis B and C viruses, and later,
HIV) that could compromise the safety of the recipient, but also infectious agents that were,
in  immunocompetent  individuals,  easily  kept  in  check  such  as  the  Epstein-Barr  Virus
(EBV), Cytomegalovirus (CMV) and others. With the advancement of HSC-based therapies
it  became clear  that  not  only  the  degree  of  compatibility  between  the  donor  and  the
recipient, but also the number of cells per kilogram of body weight of the patient (cell dose)
mattered in the success of  a perspective transplantation.  Therefore,  transplantations of
even perfectly matched HSCs could be unsuccessful if  the donor cells were not over a
certain cell dose limit. With this, the role of alloreactive T-cells present in HSCs and organ
transplants for achieving therapeutic eﬀect in haematological malignancies and the role of
th
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carriership of premalignant rearrangements in the genome of the cells of the graft came
into focus. As it turned out, these factors may predetermine the risk of severe complications
of  HSC  transplantations  such  as  graft-versus-host  disease  (GVHD)  and  secondary
leukaemia. When multipotent (MSCs) and pluripotent stem cells (ESCs and iPSCs) began
to be contemplated as a base for development of potential therapies, multiple new safety
concerns emerged. Cell preparations derived from pluripotent stem cells may contain trace
amounts of undiﬀerentiated cells with signiﬁcant carcinogenic potential. With MSCs, there
may be another concern related to the low rates of survival of transplanted cells, needing a
repeat transplantation and may potentially result in other adverse eﬀects. Eventually, the
largest determinant of applicability for potential stem cell therapies for treatment came not
from the beneﬁt(s) to the patient, but rather the incidence and degree of adverse eﬀects
from the therapy.
It was then clear early on that whether the transplanted cells would engraft and whether
they would cause short or long term beneﬁts (or detrimental eﬀects) depended on inherent
characteristics  of  the  tissues  of  the  donor  and  the  recipient.  These  characteristics
apparently extended  beyond  tissue  compatibility  and  carriership  of  infectious  agents
(although these are important) and are related essential factors that determine the chances
of survival of the donor cells in an allogenic environment and have the capacity to generate
diﬀerentiated progeny that may repopulate cell niches in the recipient. There may yet be
another factor determining the chances for success in cell and transplantations that is still
largely underestimated; namely, the individual capacity of repair of DNA damage (individual
repair capacity, IRC). Essentially, the capacity of a cell to proliferate is determined by its
capacity to detect and repair any damage to its DNA, as DNA is a very potent signal for
enforcement  of  cell  cycle  arrest,  DNA repair  and/or  apoptosis.  At  the  same time,  the
carcinogenic  potential  of  a  cell  is  also  determined  by  the  capacity  for  DNA repair,  as
carcinogenesis results from accumulation of  discrete molecular events that,  each taken
separately, are subject of control of the cellular mechanisms of checking for the presence
of genomic damage and the management of genomic integrity. Analysis of the individual
repair capacity of the cells in a graft, and of the recipient of allogenic cells and tissues may
provide additional information about the chances of success of the transplantation and the
potential  adverse eﬀects for  the particular patient.  This may allow a ‘ﬁne-tuning’  of  the
therapeutic strategy in order to suit the individual needs of the patient.
2. The Discovery of Individual Repair Capacity
In the last third of the 20  century, DNA repair proved itself as a fundamental process in
living  cells,  probably  no  less  important  as  the  triad  of  replication,  transcription  and
translation that made up the famous central dogma of molecular biology as formulated by
Francis Crick in 1970. After it became clear that a molecular defect in a single gene coding
for  a  protein  functioning  in  DNA  repair  could  be  associated  with  severe  early-onset
systemic  disease  (CLEAVER  1968),  and  later,  that  inherited  defects  in  the  tumour-
suppressor gene RB1 were associated with development of retinoblastoma (Fung et al.
1987),  it  was believed that  all  genetic  alterations that  aﬀected genes of  DNA damage
th
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detection and repair had immediate adverse eﬀects on the phenotype. This meant that
there could be very little degree of polymorphism in genes coding for proteins of  DNA
repair and maintenance of genomic integrity. Even before the discovery of the ﬁrst 'disease
of DNA repair' (xeroderma pigmentosum, deﬁned as a disease of DNA repair by Cleaver in
1968), it was reported that exposure to environmental carcinogens such as tobacco smoke
resulted in very diﬀerent rates of occurrence of lung cancer in age-matched males and
females  (Haenszel  et  al.  1962,  Haenszel  and  Taeuber  1964).  It  was  then  shown that
cultured lymphocytes isolated from clinically healthy human volunteers repaired damage at
very diﬀerent rates,  with lymphocytes isolated from females showing generally superior
performance with regard to removing DNA damage than lymphocytes isolated from age-
matched males (Pero et al. 1978, Pero and Östlund 1980). Clearly, there was individual
variance in the capacity to repair genotoxic damage determined by genetic makeup of the
individual, but the individual components were not known before the early 1990s, when a
gene previously known to be mutated at a high rate in human cancers was identiﬁed as the
culprit in a rare hereditary cancer syndrome (Li-Fraumeni syndrome) (Baker et al. 1989,
Malkin  et  al.  1990)  was  found  to  contain  a  very  common polymorphism that  was  not
associated  with  any  immediate  eﬀects  on  the  phenotype  (namely,  the  Pro72Arg
polymorphism in the TP53 gene, rs1042522) (Ara et al. 1990). Later, it was shown that
carriership of either allele of the TP53 Pro72Arg polymorphism showed signiﬁcant variance
in the biological properties of the resultant p53 protein (Thomas et al. 1999). This was only
the beginning of the studies on the role of IRC in human health and disease. It had later
become clear that the capacity for DNA repair and management of genomic integrity in
humans  could  have  signiﬁcant  eﬀects  on  the  risk  for  development  of  many  common
diseases with late onset, such as diabetes and cancer (Roy et al.  2007, Petkova et al.
2011b, Schiewer and Knudsen 2016), cardiovascular disease (Chelenkova et al. 2014, Wu
and Roks 2014), neurodegenerative disease (Coppedè and Migliore 2015, Nayyar et al.
2015);  and  that  it  could  potentially  reﬂect  on  the  susceptibility  for  disease  in  diﬀerent
individuals, and at diﬀerent ages (Cherdyntseva et al. 2010, Chakarov et al. 2012, Petkova
et al. 2013) and the outcomes of diﬀerent genotoxic treatments (Kan and Zhang 2015, Velic
et al. 2015, Petkova et al. 2014b). DNA damage repair pathways began to be regarded as
useful therapeutic targets in cancer therapy, (Khalil et al. 2012, Khalil et al. 2012b, Khalil et
al. 2012c, Gavande et al. 2016). Outcomes of genotoxic therapies with myeloablative intent
and the potential complications of therapy with haematopoietic stem cells were found to
depend on the capacity of the recipient to repair the damage inﬂicted by myeloablative
regimens (Arora et al. 2010). With the development of methodologies for derivation and
maintenance  of  stem  cells  in  culture  emerged  issues  related  to  the  'stemness'
characteristics  of  cultured  stem  cells,  including  preservation  of  their potential  for
proliferation and diﬀerentiation and the minimisation of the carcinogenic properties of cells
with inherent  tumorigenic potential  such as ESCs and iPSCs. All  these aspects of  the
biology of cultured stem cells are directly dependent on their capacity of cultured cells to
detect and repair genomic damage. With the rapid increase of the number of stem cell lines
available for research and, potentially, for clinical applications, analysis of the individual
capacity for repair of DNA damage may be helpful in identiﬁcation of cell lines that are likely
to proliferate stably in culture with minimal risk of cancerous transformation. The interest in
the role of  IRC in stem cell  biology,  and potentially  as a factor  for  their  use in clinical
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applications in  the future,  has only  recently  begun.  However,  the number  of  published
reports in the ﬁeld is still low. There could be little doubt however, that the capacity to detect
and repair DNA damage may become one of the key factors in the assessment of the
suitability for a batch of collected haematopoietic, mesenchymal stem cells or a pluripotent
cell line to be used for clinical purposes. Below we will try to summarise the present state
of  the  scientiﬁc  knowledge  about  the  role  of  IRC  in  the  success  of  stem  cell
transplantations and the potential adverse eﬀects; and address the potential issues in the
ﬁeld.
3. The Role of IRC as a Factor Determining the Outcome of HSC
Transplantations
Thanks to the improved methodology of HLA typing, analysis of blood-borne infections and
post-transplantation therapies, the survival of patients that have had received HSCs has
grown signiﬁcantly. The 5-year survival rates vary between 30 and 75%, depending on the
degree of HLA match, the cell  dose per kg body weight of  the patient,  the age of the
patients, their general status, the type of the underlying disease and the type of the graft
(stem cells from bone marrow, peripheral blood or cord blood) (Serna 2003, Gibbons 2005,
Leung et al.  2011). The prolonged post-transplantation survival  brought to attention yet
another type of complication in transplanted patients, namely, chronic GVHD, development
of leukemia originating from donor cells and, in autologous transplantation for treatment of
haematological  malignancies,  recurrence  of  the  initial  disease  because  the  autologous
cells contained the transformed clone. As it turned out, individual capacity of repair of DNA
damage  may  be  another  factor  determining  the  chances  for  success  of HSC
transplantations. On the one hand, this is related to the fact that the recipient of HSCs is
more  often  than  not  subjected  to  genotoxic  treatments  in  order  to  achieve  partial  or
complete myeloablation. Individuals with IRC that are lower than average (sometimes even
subtly lower) may exhibit severe, even life-threatening adverse eﬀects from myeloablative
regimens, even if they are generally well-tolerated, and may be still left with a considerable
amount of tissue damage at the time of transplantation. The latter may be associated with
severe post-transplantation complications such as high-grade GVHD. On the other hand,
an inferior capacity for repair of DNA damage in the cells of the graft, coupled with the
lifelong  immunosuppressive  regimens  that  are  usually  administered  to  patients  with
transplanted tissues and organs, may increase the risk of development of malignancies
originating from donor cells. An assessment of the individual repair capacity of the recipient
(ideally, before and at the end of the myeloablation cycle) and of the cells in the graft may
potentially  assist  the clinician in  the decision-making of  the eligibility  of  the patient  for
certain treatments. This assessment includes an evaluation of the chances for potential
beneﬁts and the anticipation of the adverse treatment-related eﬀects, both in the short term
(treatment-associated  toxicity)  and  in  the  long  term  (high-grade  GVHD,  donor  cell
leukaemia).
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3.1 Association of Individual Capacity for Repair of Genotoxic Damage and the
Risk for Development of High-Grade Graft-Versus-Host Disease (GVHD)
GVHD is a serious post-transplantation complication that develops in immunocompromised
patients that have received a transplant of allogeneic immunocompetent haematopoietic
cells. Unlike regular tissue and solid organ transplantations where the transplanted organ is
attacked by the immune system of the host, GVHD has an immune conﬂict between the
host and recipient in reverse, where the immunocompetent cells in the graft recognise and
target the host tissues. GVHD may be acute or chronic (depending on whether it develops
within 100 days of the transplantation or afterwards) and its severity may signiﬁcantly vary;
from mild (grade I) to severe (grade IV). GVHD typically targets three organs and systems;
skin and mucosa, the liver and/or the gastrointestinal tract as a whole. Acute GVHD may be
severe (sometimes life-threatening) and is generally associated with decreased survival. It
is believed that the tissue injury caused by the genotoxic conditioning regimens prior to
HSC transplantation is the major pathogenetic factor in the development of acute GVHD
[reviewed  in  (Jacobsohn  and  Vogelsang  2007).  Lower-than-average  capacity  for  DNA
damage repair  may  be  associated  with  increased  revels  of  residual  tissue  damage in
patients  undergoing  myeloablation  prior  to  HSC  transplantation.  One  polymorphism  in
genes  coding  for  proteins  responsible  for  repair  of  DNA  damage  have  already  been
implicated in the pathogenesis of severe (grade II-IV) acute GVHD - namely, the rs6844176
C-to-T polymorphism in subunit 1 of replication factor C (RFC-1) (Arora et al. 2010). RFC-1
is a component of the BRCA1-associated genome surveillance complex (BASC) that scans
the  genomic  DNA  for  the  presence  of  structural  damage  in  DNA,  activates  damage-
response pathways and recruits DNA repair machinery to the damage site (Wang et al.
2000).  Recipient  carriership  of  the  2351insT  (rs41376448)  allele  of  the  HMGB1 gene
(coding for a master transcription regulator protein tightly linked with DNA repair) was found
to reduce the risk of moderate-to-severe acute GVHD, whereas homozygous carriership of
the same allele in the donor cells was associated with chronic GVHD (Kornblit et al. 2010).
Unlike  acute  GVHD,  chronic  GVHD  (provided  that  it  is  kept  under  control)  may  be
associated with increased survival after transplantations of allogeneic HSCs. In the study
of Arora et al. cited above, carriership of the 1300+104A>G (rs1805410) polymorphism in
the PARP1 gene was found to be associated with a 2-fold increase of the risk of chronic
GVHD in patients with transplanted HSCs. Poly-(ADP-ribose)-polymerase family member 1
(PARP1)  is  damage  sensor  molecule  that  activates  p53-dependent  pathways  in  the
presence of DNA breaks, induces remodelling of chromatic structure in the area of the
lesion site and recruits the DNA repair machinery (Valenzuela et al. 2002). The genotoxic
agents  most  commonly  used  in  myeloablative  regimens  are  alkylating  agents
(cyclophosphamide,  ifosfamide,  melphalan and others),  adduct-forming agents  inducing
accumulation of double-strand breaks in DNA (anthracyclines, mitoxanthrone) and ionising
radiation (separately or in combination). All these agents induce structural damage in DNA
(base  modiﬁcation,  strand breaks),  hence  the  importance  of  the  normal  functioning  of
damage-sensing  proteins  and  complexes  for  the  repair  of  tissue  damage  inﬂicted  by
myeloablative regimens. Several common polymorphisms in key genes coding for proteins
of the base excision repair (BER - functioning in repair of oxidised bases) have been shown
to modulate treatment-related mortality (including GVHD-related mortality) in patients with
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allogeneic HSC transplantations (Thyagarajan et al. 2010). Four of these polymorphisms
(namely, the rs159153 C-to-T polymorphism in the promoter of the hOGG1 gene (coding
for  a  glycosylase  removing  8-oxoguanine  and  formamidopyrimidines  from  DNA),  the
rs3135974 A-to-G polymorphism in the LIG3 gene, coding for ligase ІІІ (the primary ligase
of BER); the rs3219463 A-to-G and the rs3219476 G-to-T polymorphisms in the MUTYH
gene (coding for a DNA glycosylase resolving A/G mispairs) were found to increase the risk
for transplant-related mortality in patients with allogeneic transplantations of HSCs. In the
same study, carriership of two other polymorphisms (rs167715 C-to-T and rs2374327 A-to-
T, both in the gene TDG coding for a glycosylase catalysing the removal of T from G/T, C/T
and  T/T  mispairs)  were  associated  with  increased  chances  for  post-transplantation
survival.  Apparently,  the  individual  capacity  for  repair  of  base modiﬁcations  along with
strand break repair are among the key factors determining the degree of tissue damage
after conditioning regimens, and respectively, the risk for post-transplantation survival. An
assessment  of  basic  parameters  of  IRC  and  speciﬁcally,  the  proﬁciency  of  repair  of
damage  managed  by  BER  and  break  repair  pathways  may  assist  in  the  process  of
selection and personalisation of a conditioning and post-transplantation regimens as well
as  in  the  management  of  the  potential  adverse  eﬀects,  both  before  and  after  HSC
transplantation.
3.2 Association of Individual Capacity for Repair of Genotoxic Damage and the
Risk for Development of Secondary Leukaemia after HSC Transplantations
After  large-scale  collection  and  storage  of  haematopoietic  stem cells  from cord  blood
became possible,  it  oﬀered seemingly limitless opportunities for  treatment  of  malignant
haematological  disease  with  one's  own  (immunologically  100  %  compatible)
haematopoietic cells. Thus, autologous use of HSCs was associated with particularly high
hopes for  successful  transplantation outcomes. Soon it  became apparent that  for  most
types of  childhood leukaemia,  the abnormal  clones carrying pre-leukemic chromosome
rearrangements  were  already  present  in  neonatal  blood  spots  of  infants  that  later
developed leukaemia and therefore were likely to have arisen in utero (Gale et al. 1997). It
was later conﬁrmed that clones carrying chromosome translocations, that may later result
in leukaemia, were often generated in the course of normal intrauterine development (Mori
et al. 2002, Gruhn et al. 2008). Expansion of speciﬁc leukocyte clones also turned out to be
quite  common,  as  a  signiﬁcant  proportion  of  healthy  people  were  found  to  carry  an
expanded non-aberrant lymphocyte clone that amounted to >10% of the total lymphocyte
population (Nakano et al. 2004). Interestingly, chromosomal aberrations commonly seen in
leukaemia (monosomy 7, trisomy 8, loss of the long arm of chromosome 5 and deletions of
portions  of  the  17p13  locus  containing  the  TP53  tumour  suppressor  gene)  were  not
identiﬁed  in  HSCs  collected  from  peripheral  blood  of  adult  patients  that  received
myeloablative  treatment  and  subsequent  autologous  transplantation  of  HSCs  from
peripheral blood and went on to developing leukaemia or myelodysplastic syndrome (MDS)
(Weber et al.  2000). The latter may mean that the expansion of clones with signiﬁcant
leukemic potential are suppressed in the course of individual life. At present, autologous
HSC transplantations are not recommended for most types of leukaemia, with the possible
exception  of  patients  with  acute  myeloid  leukaemia  placed  in  the  "favourable"  and
8 Reynolds L
"intermediate"  risk  group  by  cytogenetics  (deﬁned  by  absence  of  speciﬁc  genomic
rearrangements that are usually identiﬁed in autologous haematopoietic progenitors and
the presence of less than 3 diﬀerent clonal chromosomal abnormalities) (Burjanivova et al.
2006, Tummala et al. 2012, SABTY et al. 2012). In any case, the sole presence of a pre-
leukemic clone in the HSCs of a healthy infant do not necessarily mean there is a 100%
risk for development of leukaemia later in life. The case is completely diﬀerent when HSCs
are transplanted in a patient whose immune system has been signiﬁcantly weakened, or
altogether destroyed in the course of myeloablative treatments prior to transplantation. The
functioning of the newly transplanted immunocompetent cells are suppressed by the post-
transplantation therapeutic regimens. The risk for transformation of the pre-leukemic clone
received  with  the  autologous  graft  into  an  invasive  leukemic  clone  may  be  greatly
enhanced  in  immunocompromised  patients,  resulting  in  recurrence  of  the  primary
malignancy.  The  latter  signiﬁcantly  decreases  the  potential  value  of  autologous
transplantation of  HSCs in  leukaemia,  except  in  select  groups.  Of  course,  since latent
chromosomal  translocations  with  carcinogenic  potential  may  also  exist  in  HSCs  from
clinically  healthy  donors,  donor  cell  leukaemia  may  also  occur  after  allogeneic
transplantation  of  HSCs  from  healthy  donors.  Several  dozens  of  cases  of  leukaemia
(originating  from  allogeneic  donor  cells  transplanted  for  the  purposes  of  treatment  of
leukaemia, lymphoma or aplastic anaemia) have already been reported (Neglia et al. 1991,
Matsunaga  et  al.  2005,  Bobadilla-Morales  et  al.  2015).  The  risk  for  development  of
secondary  haematological  malignancy  is  likely  to  be  higher  in  autologous  as  well  as
allogeneic HSCs carrying genetic polymorphisms conferring lower-than-average capacity to
repair genotoxic damage. The data about the role of polymorphisms in genes coding for
key genes in DNA repair and maintenance of genomic integrity is still very limited. However
there is a report on donor cell leukaemia in a recipient that received a transplant from an
HLA  matched  sibling  carrying  the  repair-deﬁcient  alleles  of  the  polymorphisms  XPD
Lys751Gln  (rs1052559)  and  XRCC3  Thr241Met  (rs861539)  in  their  homozygous  state
(Diamond et al. 2011). The XPD (ERCC2) gene codes for one of the two helicases that
unwind DNA in the vicinity of the lesion site, allowing free access of the machinery for
repair by nucleotide excision (NER), whereas XRCC3 codes for a key protein of repair by
homologous  recombination.  Carriership  of  these  two  polymorphisms has  already  been
identiﬁed as a risk factor for development of leukaemia, increasing the risk > 2-fold for XPD
Lys751Gln and > 3.5 fold for XRCC3 Thr241Met, respectively (Hamdy et al. 2011, Bănescu
et al. 2014). Additional research is required in order to conﬁrm the report of Diamond et al.
2011, but it could be expected that some of the polymorphisms in other genes responsible
for identiﬁcation and repair  of  DNA damage and maintenance of genomic integrity that
have been already implicated in the pathogenesis of leukaemia, such as TP53 Pro72Arg,
MDM2  SNP309  (rs2279744),  XRCC1  Arg194Trp  (rs1799782),  hOGG1  Ser326Cys
(rs1052134), CCNH Val270Ala (rs2230641) (Enjuanes et al. 2008, Batar et al. 2009, Do et
al.  2009, Li et al.  2011) and polymorphisms that have been associated with diﬀerential
outcomes after haematological disease and HSC transplantations (the above mentioned
TP53 Pro72Arg and also HMGB1 3814 C-to-G (rs2249825); XPC Lys939Gln (rs2228001)
and XPF C673T (Kornblit et al. 2010, Xu et al. 2012, McGraw et al. 2015, Bănescu et al.
2016)  and  potentially,  others  may  modulate  the  risk  for  development  of  donor-cell
leukaemia in patients with HSC transplantations. Carriership of the variant (deletion) allele
The success of stem cell transplantations and the potential post-transplantation ... 9
of the -1377delA (rs41369348) polymorphism in the HMGB1 gene was associated with 2-
fold increased risk of  relapse of  the primary haematological  malignancy (Kornblit  et  al.
2010).
Recently, it was reported that deﬁciency of exonuclease 1 (functioning in 5'- end resection
of  DNA  ends,  a  key  enzyme  activity  in  mismatch  repair  and  repair  by  homologous
recombination) had no eﬀect on quiescent murine HSCs, but in dividing HSCs resulted in
increased sensitivity to DNA damage and rapid cell death after genotoxic challenge (Desai
et al. 2014). Thus, deﬁciencies of EXO1 conferred by carriership of genetic polymorphisms
may have little or no eﬀect in healthy individuals (maintaining the majority of their HSC
population in the quiescent state at any given time) but may have signiﬁcant eﬀect when
EXO1-deﬁcient cells have been transplanted and stimulated into rapid proliferation. Several
polymorphisms  in  the  human  EXO1  gene  have  been  described  so  far  (Glu589Lys
(rs1047840), Leu757Pro (rs9350), and others) that were related to increased propensity to
cancer (Jin et al. 2008, Bau 2009, Haghighi et al. 2010); therefore, it is possible that EXO1
polymorphisms may play a role in both the chances for engraftment of HSCs and the risk
for secondary malignancies after transplantation.
4. Potential Role of IRC as a Factor Determining the Survival of
Transplanted Mesenchymal Stem Cells
Mesenchymal  stem  cells  are  a  speciﬁc  type  of  multipotent  cells  originating  from  the
embryonic mesenchyma. MSCs may be isolated from the amniotic ﬂuid, the Wharton's jelly
of the umbilical cord, the placenta, the stroma of the adult bone marrow, the dental pulp
and  the  gingiva.  MSCs are  not  deﬁned by  strict  criteria  (e.g.  expression  of  a  speciﬁc
surface receptor) but are, in fact, rather a heterogeneous population. They adhere to plastic
surfaces  in  vitro,  are  capable  of  spontaneous  diﬀerentiation  along  the  osteogenic,
chondrogenic and adipogenic lineages and express a subset (but not all) of the surface
markers of the skin and lung ﬁbroblasts (Dominici et al. 2006). Targeted diﬀerentiation of
MSCs  may  yield  other  cell  types  as  well,  such  as  insulin-producing  pancreatic  cells,
diﬀerent kidney-speciﬁc cell types such as tubulocytes and podocytes, cardiomyocytes, and
other cell types (Sun et al. 2007, Pereira et al. 2008, Brunner et al. 2008, Asanuma et al.
2010).  MSCs possess  signiﬁcant  potential  for  use  in  the  regenerative  and  reparative
medicine  because  of  their  versatility.  At  the  same time,  they  present  signiﬁcantly  less
ethical  challenges  than  embryonic  stem  cells  with  regard  to  their  collection.  Their
proliferative  potential  is  higher  compared  to  somatic  cells  but  is  nowhere  near  to  the
capacity for proliferation as ESCs; therefore, their use is expected to be associated with
much less potential adverse eﬀects than ESCs. There are, however, two serious limitations
to the use of MSCs in clinical applications; their poor viability after transplantation in injured
tissues and their  poor  migratory  capacity,  meaning that  their  beneﬁcial  eﬀects  may be
short-lived and are unlikely to extend beyond the narrow limits of the lesion site (Lee et al.
2015). In animal models of ischemic myocardial infarction, less than 6 % of the autologous
MSCs injected at day 0 were identiﬁable by day 10 in pigs (Gyongyosi et al.  2008). In
immunodeﬁcient mice, the results are even poorer, with < 0.5 % of the transplanted human
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MSCs surviving by day 4 post-transplantation (Toma 2002). In a small group of human
patients with myocardial infarction that received intracoronary infusion of MSCs, no more
than 2.5 % of the infused cells were identiﬁable at the lesion site within 75 minutes post-
infusion (Hofmann 2005. This and other similar reports brought about the concept that the
MSC  did  not  actually  integrate  stably  within  the  injured  tissue  but,  rather,  exerted  a
stimulating eﬀect on the regenerative processes at the lesion site (neo-angiogenesis in
myocardial  injury,  axonal  regeneration  in  spinal  cord  injury,  etc.),  then  habitually  die
(Kamada et al.  2005, Tang et al.  2009, Poncelet et al.  2010). Better results have been
recently obtained with human bone marrow and umbilical cord MSCs transplanted in rat
spinal  cord  injury  models,  with  cells  surviving  at  least  8  weeks  post-transplantation,
producing an improvement of symptoms with regard to neuropathic pain and preventing
spinal cord cavitation (Youseﬁfard et al. 2016). There is a pilot phase I on-going study into
the eﬀects of intrathecal injection of autologous MSCs from bone marrow in a small group
of human patients with spinal cord injury. Also, there are phase 1/2 and 2a clinical trials of
autologous transplantation of  mesenchymal  stem cells  secreting neurotrophic factors in
patients with amyotrophic lateral sclerosis, but the results so far are expressed in terms of
safety (lack of adverse eﬀects) rather than any measurable beneﬁcial eﬀects (Satti et al.
2016, Petrou et al. 2016).
There have been several reports about the potential of use of allogeneic bone marrow-
derived MSCs in patients with severe, treatment-refractory GVHD as a means to inhibit the
T- and B-cell  mediated immune response (Chen et al.  2015, Hashmi et al.  2016).  The
results  however,  remain  controversial,  with  some groups  reporting  beneﬁcial  eﬀects  of
MSCs treatments and other groups ﬁnding no diﬀerence in the success rates between
patients that received the treatments and controls (Kim et al. 2013).
The capacity for repair of DNA damage and maintenance of genomic integrity is a key
factor  determining  the  cell  survival  under  physiological  and  pathological  conditions.  A
recent  study  reported  that  in  vitro  culturing  had  signiﬁcant  eﬀects  on  the  capacity of
cultured  MSCs to  repair  DNA damage,  speciﬁcally  double  strand  DNA breaks  (DSBs)
(Hare et  al.  2016).  Speciﬁcally,  the authors of  the cited study reported that  in cultured
MSCs,  the  eﬃciency  of  both  mechanisms  used  for  repair  of  DSBs  -  homologous
recombination (high-ﬁdelity) and nonhomologous end joining (NHEJ, error-prone) declined
with repeated passaging. DSBs are believed to be the most toxic, and respectively, the
least tolerated of all types of DNA damage. In most types of cells the presence of more
than a couple of DSBs is a potent signal for activation of the apoptotic pathways. There are
cells  where  the  temporary  presence  of  high  levels  of  DSBs  may  be  normal  but  it  is
generally restricted to a speciﬁc phase of the life cycle of the cell.  In such cases (e.g.
immune cells, quiescent oocytes), the mechanisms for activation of DNA damage response
pathways  may  be  speciﬁcally  suppressed  or  maintained  at  baseline  level  only  for  the
duration  of  the  speciﬁc  phase  (Küppers  and  Dalla-Favera  2001,  Petkova  et  al.  2015).
Cultured cells are often subjected to freezing using cryoprotectors with genotoxic potential
such as DMSO. Thus, it is possible that the poor survival of transplanted MSCs may be
related to a suppression of the mechanisms for repair of toxic DNA lesions in the course of
their  derivation  and  culturing.  When  transplanted  at  sites  of  injury,  the  presence  of
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inﬂammation (accompanied with high levels of oxidative stress) may put an additional strain
on the already deﬁcient DNA repair system of the MSCs and may accelerate their demise,
thereby diminishing their potential to exert their beneﬁcial eﬀects. There is a considerable
degree of population polymorphism with regard to genes coding for key proteins of repair of
strand breaks such as XRCC2, XRCC3, NBS1 (repair by homologous recombination) and
LIG4 and XRCC4 (repair by non-homologous end joining). Typing of MSC lines by the most
common polymorphisms in these genes associated with a decreased capacity for repair of
DSBs such as XRCC2 rs10234749 (C-to-A), rs6464268 (T-to-C), rs3218373 (G-to-T) and
Arg188His (rs3218536); XRCC3 Thr241Met; NBS1 Ile171Val (rs61754966) and Arg215Trp
(rs34767364) polymorphisms; LIG4 Thr9Ile (rs1805388),  Ile658Val  (rs2232641) and the
synonymous  Asp568Asp  polymorphism  (C-to-T, rs1805386);  the  XRCC4  Ala247Ser
(rs373409) polymorphism and the pro-apoptotic allele of the TP53 Pro72Arg polymorphism
may assist in the selection of MSC lines with superior capacity for DNA repair that may,
potentially, exhibit improved survival upon transplantation.
5. The Role of IRC in the Establishment, Maintenance of
Pluripotent Stem Cells Used in Research and Potentially Clinical
Applications
At present, there are two major types of pluripotent stem cells that are routinely used in
research:  embryonic  stem cells  (ESC) and induced pluripotent  stem cells  (iPSC).  Both
types are characterised by a proliferative capacity, signiﬁcantly exceeding the Hayﬂick's
limit  for the species and capability of producing all  types of diﬀerentiated cells that are
normally seen in the adult organism. There may be signiﬁcant ethical issues associated
with the research on human ESCs, as the majority of validated methodologies for their
derivation are based on the destruction of viable human embryos. In comparison, there is
very little ethical controversy about the establishment and use of iPSCs, as they may be
derived by diﬀerentiated cells by reprogramming back to the pluripotent state. At present,
most  of  the  clinically  signiﬁcant  types  of  precursors  of  diﬀerentiated  cells  (neural
progenitors,  cardiomyocytes,  precursors  of  osteocytes,  chondrocytes,  adipocytes  and
insulin-secreting pancreatic cells, diploid and haploid cells of the spermatocyte lineage, and
others) have been successfully derived from murine and human ESC (Phillips 2003, Kroon
et al. 2008, Elkabetz and Studer 2008, Jukes et al. 2010, Easley et al. 2012), with the
notable exception of human oocyte precursors that proved to be a signiﬁcant challenge for
modern stem cell engineering (Virant-Klun et al. 2011, Petkova et al. 2014a). In a similar
fashion,  virtually  all  types  of  diﬀerentiated  cells  have  already  been  derived  from iPSC
(Arabadjiev et al. 2014, Yoder 2015, Hossain et al. 2016 ,Hu et al. 2015) gain, derivation of
human germline cells form of iPSC presents a problem, unlike murine iPSC-derived germ
cell precursors that were shown to diﬀerentiate readily into fully functional spermatozoa and
oocytes (Ishii 2014).
Diﬀerentiated cells derived from pluripotent cells are very valuable in modern research as a
model system for the mechanisms of cell  proliferation, migration, diﬀerentiation, cell-cell
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and  cell-matrix  interactions,  cellular  senescence  and  death  under  physiological  and
pathological conditions, and they have high potential for future clinical applications (Trifonov
et al. 2013, Zhelev 2015, Falconer and Zhelev 2015). Nevertheless, to date very few cell
products  derived  by  diﬀerentiation  of  pluripotent  cells  have  been  used  in  any  type  of
oﬃcially  approved  treatment  or  a  clinical  trial,  mainly  because  of  the  inherent  risk  for
induction  of  cancer  growth  in  the  recipient,  originating  from  trace  amounts  of
undiﬀerentiated cells  in  the cell  product  (Schwartz  et  al.  2015,  Schulz  2015).  Diﬀerent
techniques for identiﬁcation and elimination of leftover undiﬀerentiated cells have already
been  developed  (Cheng  et  al.  2012,  Christine  LaVanne  2013, Wu  et  al.  2014).
Nevertheless,  there  are  two essential  problems that  may additionally delay  the  use of
preparations derived from pluripotent cells for clinical purposes. One of the problems is
related to that fact that until several years ago (and even now) the majority of routinely used
pluripotent stem cell  lines have been derived and propagated in conditions that impede
their further use in any applications in they may be used for treatment of human beings
(use of 'homemade' media with undeﬁned and unstandardised composition and/or contact
with products of animal origin, such as fetal bovine serum, murine feeders, trypsin from
porcine pancreas, etc.) According to a report published in 2012: “...considering the ﬂood of
new [ESC] lines in the US and abroad...researchers continue to rely on a few lines derived
before the turn of the century" (DeRouen et al. 2012) most all of these lines were created in
conditions  that  could  not  be  described  as  "xeno-free",  the  latter  being  an  obligate
requirement  for  any  cell  product  that  may  potentially  be  used  in  treatment  of  human
disease or in human regenerative medicine in order to avoid transmission of infectious
agents of  animal  origin.  The second problem is  closely  related to the ﬁrst  and is  also
summarised in  the quotation cited above.  The fact  is  that  most  of  the present  human
embryonic stem cell lines available for research have been maintained in culture for a very
long time (years and decades). Therefore, this may, through constant passaging, have lost
some of  their  initial  characteristics  and may have acquired  some undesired  traits.  For
example,  in  2010 it  was reported that the ﬁrst  Swiss ESC line derived only two years
previously,  in  2008,  along  with  several  routinely  used  hESC  lines,  exhibited  changes
consistent  with  carcinogenic  transformation  (trisomies  for  several  chromosomes,
intrachromosomal loss and gains of genetic material, and other, less conspicuous genomic
changes)  (Hovatta  et  al.  2010).  Similar  genomic  rearrangements  have  been  already
noticed in other hESC lines that have been kept in culture for years and decades (Draper et
al.  2003,  Spits  et  al.  2008).  Apparently,  genomic instability  is  a  standing problem with
ESCs, especially in lines that have been established some time ago. A similar problem may
emerge with iPSCs, although being a more recent discovery, the main source of genomic
instability  may  not  be  the  prolonged  culturing  and  repetitive  passaging,  but rather  the
eﬀects related to the reprogramming of diﬀerentiated cells back to the pluripotent state.
iPSC cells exhibit an expression proﬁle overlapping with the expression proﬁle of cancer
cells and this may persist even in their diﬀerentiated derivatives (Malchenko et al. 2010,
Ghosh et al. 2011). Moreover, iPSCs may be more prone to senescence mediated by p53-
dependent pathways. The latter were shown to be directly activated in the course of cellular
reprogramming by the expression of the major factors used for induction of pluripotency
(the Yamanaka factors OCT4, SOX2, KLF4, c-MYC or other combinations) (Banito et al.
2009, Hong et al. 2009). Thus, potential use of existing ESC lines may be associated with
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an increased risk for induction of tumorigenesis in the recipient, whereas the use of iPSC
may  also  confer  risk  for  rapid  loss  of  proliferative  and  diﬀerentiation  capacity  and  for
shortened  lifespan  (and  respectively,  diminished  functionality)  of  the  diﬀerentiated  cell
products. For the past few years, many researchers worldwide have recommended that the
currently  used  pluripotent  lines  may  be  unsuitable  for  clinical  applications  and  that
establishment of ESC and iPSC lines ought to start anew, in controlled and strictly xeno-
free conditions (Lãser et al. 2009,Arabadjiev et al. 2010, Abbasalizadeh and Baharvand
2013, Chakarov et al. 2014c, Desai et al. 2015). Other authors focus their attention upon
the mutation rate of stem cell lines and advise that quantitative evaluation of the mutation
rate ought to become a routine criterion in assessment of the properties of the pre-existing
and the newly established lines and speciﬁcally, in the decision-making about its potential
suitability for medical applications (Sverdlov and Mineev 2013, Heslop et al. 2015).
The risk in occurrence of mutations and genomic instability in a cultured cell line depends,
on the culturing conditions and the number of passages, as well as the intrinsic properties
of  the  cells.  ESCs  have  an  inherently  high  proliferative  potential  and  relatively  short
doubling time with a shortened G1 phase. The latter means that the severity of the pre-
synthetic checkpoints for DNA damage that are particularly important in most dividing cells
is relaxed (in human stem cells) or altogether abolished (in rodent stem cells) and as a
result,  DNA damage may accumulate in  the course of  rapid division (Arabadjiev et  al.
2012). In addition, embryonic stem cells are often treated with various chemical agents
(e.g. cryoprotectors such as DMSO) that may have genotoxic properties. In vivo, embryonic
cells that have sustained damage beyond a certain threshold are routed towards apoptosis
(which may cause the death of the embryo) or may be induced towards diﬀerentiation, as
the G1/S checkpoints are fully operational in diﬀerentiating cells. In vitro however, under
conditions speciﬁcally designed to maintain the undiﬀerentiated state, embryonic cells that
have accumulated signiﬁcant amounts of damage may lose their proliferation capacity and
eventually die, or may ﬁnd ways to ignore or ignore the mechanisms that dictate that a
damaged cell must die - in other words, they may become transformed. Inherent traits that
increase the risk for introduction of mutations and/or for increased genomic instability may
facilitate the process of transformation. Indeed, the mutation rates in pluripotent stem cells
have been shown to be relatively lower than the mutation rates in somatic cells, which are
believed to be due at least partly to the extensive use of the mechanism for homologous
recombination for DNA repair (Cervantes et al. 2002, Chlon et al. 2016). The latter is less
error-prone than the other mechanisms of DNA repair, mainly because it uses the high-
accuracy DNA polymerases of replication (Chakarov et al.  2014b). Nevertheless, under
conditions where the main checkpoints for presence of DNA damage are virtually non-
existent for the duration of many cell divisions, the risk for introduction of alterations in the
sequence and structure of DNA may become signiﬁcant, especially in cell lines that are
characterised  by  inherently  low  capacity  for  identiﬁcation  and  repair  of  DNA damage.
Carriership of some of the common polymorphisms in genes coding for proteins of DNA
repair and maintenance of genome integrity are known to be associated with increased
genomic instability in cultured cells - namely, the already mentioned polymorphisms XPC
Lys939Gln,  XPD  Lys751Gln,  XRCC3  Thr241  Met  and  others  such  as  XPG  (ERCC5)
Asp1104His (rs17655) and XRCC1 Arg399Gln (rs25487) (Vodicka et al. 2004, Petkova et
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al.  2013).  These,  and  potentially  other  polymorphisms  in  genes  coding  for  products
functioning in repair by homologous recombination such as XRCC2 and NBS1, may have
speciﬁc signiﬁcance in pluripotent cells relying primarily on homologous recombination to
maintain their genome in optimal condition. The C677T polymorphism in the MTHFR gene,
which has been shown to be associated with increased risk for cancer in homozygous
carriers  of  the  T  allele,  may  also  have  some signiﬁcance,  as  it  is  very  common,  the
prevalence of the TT genotype reaching 30 % in some populations (Wilcken 2003).
Studies  on  the  individual  repair  capacity  of  pre-existing,  and  speciﬁcally,  on  newly
established pluripotent  stem cell  lines,  together  with the mutation rate and the general
(phenotypic) capacity to repair DNA damage (measured by the rates of unscheduled DNA
synthesis) may be of assistance in the selection of pluripotent stem cell lines with optimal
characteristics for research purposes. This is especially true for lines that may potentially
be used in future clinical applications, in order to decrease the risk of using lines that are
inherently prone to carcinogenesis or are likely to deteriorate quickly.
Isolated  lack  of  the  expression  of  the  transcription  regulator  HMGB2  functioning  in
regulation of DNA repair and maintenance of genomic integrity was found to be associated
with increased levels of neurogenesis in brains of adult mice (Abraham et al. 2013). Thus,
analysis of the factors modulating the capacity for maintenance of genomic integrity may
aid in the development of a potential pathway for stimulation of the neuronal stem cell niche
in acute or chronic CNS trauma.
6. Methodologies of IRC Assessment – typing polymorphisms may
not be enough to assess the true capacity to repair damage
At present, several dozens of common polymorphisms in genes coding for key proteins
responsible  for  DNA  damage  identiﬁcation  and  repair  of  genomic  integrity  have  been
described and protocols for their rapid typing have been made public. It soon became clear
that the strength of the associations of these polymorphisms with human diseases and
conditions may be very diﬀerent in diﬀerent populations, and in individuals at diﬀerent ages.
While  the  former  could  among  other  things,  reﬂect  population-speciﬁc  intra-genomic
interferences between alternative alleles at diﬀerent loci, the latter was less straightforward
and was attributed by some authors to the phenomenon of 'antagonistic pleiotropy', that is
the case of one genetic trait being beneﬁcial at early age but deleterious at a later age or
vice versa (Khalil  et al. 2012a, Chakarov et al. 2014a). There was one notable case in
which  the  same  allele  of  a  single-nucleotide  polymorphism  (ERCC1  C8092A)  was
associated with opposite eﬀects on the survival of patients with the same disease treated
with the same type of agents in two independent large studies (Zhou 2004, Kalikaki et al.
2009).  These  and  similar  studies  demonstrated  that  typing  of  disparate  DNA
polymorphisms provided incomplete information about individual repair capacity. There is
no question that  the information gathered from assessment  of  the status  by individual
polymorphisms or haplotype analysis is an important part  of IRC, but this needs to be
integrated within the context of the general phenotype of the individual being tested - that
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is,  it  needed to  be  augmented  by  phenotypic  analysis.  For  the  purposes  of  individual
assessments, this could conveniently be provided by the already developed methodology
of unscheduled (non-replicative) synthesis of DNA, most commonly under conditions of
replication  blockade  (Chakarov  et  al.  1997,  MORI  et  al.  2000,  Marden  et  al.  2006,
Chakarov et al. 2011). For analysis of individual patients, these methods have the relative
inconvenience that they require living cells (e.g. ﬁbroblasts) or DNA extracted from living
cells, and that tests may need to be repeated in order to monitor the course of a disease or
a speciﬁc treatment. Nevertheless, since most patients that are for some reason, in need of
a transplant of haematopoietic cells or have at some point received a transplant, undertake
regular blood analysis in order to monitor their progress. Lymphocytes for assessment of
ICR may be made available without additional  invasive testing.  For freshly collected or
cultured cells obtaining a sample for assessment of ICR is unlikely to be an issue.
The individual capacity for repair of DNA damage plays a role in the capacity of stem cells
to renew their own population. Therefore, it may be a useful addition to the analyses for
selection of cell lines that are likely to be propagated safely, in vitro, without the added risks
for loss of the line and/or carcinogenic transformation. Again, this ought to include more
than  simple  typing  for  common  polymorphisms,  but  also  phenotypic  markers  for
proliferation potential,  such as telomere length analysis  and assessment  of  telomerase
activity  (Petkova et  al.  2011a, Chakarov et  al.  2014a).  This type of  analysis may have
diﬀerent signiﬁcance for assessment of the proliferative capacity of ESCs (expressing the
catalytic unit of telomerase (telomerase reverse transcriptase, TERT), therefore inherently
capable of maintaining telomere length) and for HSCs and MSCs (having limited or virtually
non-existent expression of TERT, therefore normally prone to telomere shortening). In аny
case, assessment of telomere length of freshly derived and cultured stem cells may assist
in the selection of cell batches and cell lines with optimal proliferative capacity, avoiding
these that may be prone to carcinogenic transformation or these that are at the limit of their
proliferative capacity and/or are genetically predisposed to rapid demise with subsequent
culturing or after transplantation.
7. Conclusions
Several  factors  determining  the  success  of  a  transplantation  have  been  identiﬁed,  but
prognostication of  the short-term and long-term outcomes are still  unreliable.  Individual
capacity for repair of DNA damage and maintenance of genomic integrity in the donor and
the recipient  may account  at  least  partly  for  the individual  variance in the response to
conditioning  therapies  and  the  associated  post-transplantation  complications  such  as
GVHD,  relapse  of  the  primary  disease,  shortened  survival  of  transplanted  cells  in
allogeneic  environments  and  the  risk  for  secondary  malignancy  originating  from
transplanted cells. Assessments of the individual repair capacity may become a useful tool
for  selection  of  the  sources for  cells  for  transplantation  in  order  to  avoid  severe  post-
transplantation complications, rapid deterioration of the graft and/or induction of cancerous
growth. This sub-ﬁeld of the studies dedicated to the role of individual repair capacity in
health  and  disease  is  still  quite  new and  a  considerable  amount  of  research  may  be
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needed in order to elucidate its role and, potentially, translate the accumulated knowledge
into clinical applications. 
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